A Phase 1, Study to Evaluate HTI-2088 Tablet

NCT03203811 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes

Interventions

DRUG: HTI-2088
DRUG: Placebo

Sponsor

Hengrui Therapeutics, Inc.